About
About START

Welcome to the START Center for Cancer Research. We are a global leader in cancer research, dedicated to the relentless pursuit of hope for patients and their families.

About

Company

Hope Hub

Leadership

Principal Investigators

Careers

Contact

Our Services

Preclinical

Early Phase
Who We Serve
Who We Serve

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment.

Visit The START Hope Hub

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment. Designed to help you understand, explore, and enroll in early-phase oncology trials, the START Hope Hub will help guide you through the clinical trial process with confidence.

Explore Hope Hub

Patients & Family

Patients

Explore Clinical Trials

About Clinical Trials

Patient Stories

Patient Advocacy Groups

Referring Physicians

Referring Physicians

Hospitals & Oncology Practices

Hospitals & Oncology Practices

Pharma

Pharma
START Locations
START Research Centers

100,000+ square feet of world-class research facilities

United States Locations

START - San Antonio

START - Midwest

START - Mountain Region

START - Carolinas

START - Dallas Fort Worth

START - New Jersey

START - New York-Long Island

START - Los Angeles

Europe Locations

START - Madrid - CIOCC

START - Madrid - FJD

START - Barcelona

START - Rioja

START - Pediatrics

START - Lisbon

START - Dublin
Resources
Resources

Stay up to date with everything at START, from blog insights and press and newsroom updates to expert-led webinars and much more.

Resources

Blog

Events

Newsroom

Press

Publications

Webinars

Featured Resources

Newsroom

Baptist Health South Florida and The START Center for Cancer Research Announce Strategic Partnership to Expand Patient Access to Early-Phase Cancer Trials

Newsroom

START Research Expands Clinical Leadership with Appointment of Dr. Neel Belani as Clinical Investigator at START New Jersey
Hope Hub
Find a Trial

Nehal Lakhani, MD, PhD

Nehal J. Lakhani, MD, PhD

Midwest, Principal Investigators, United States / Joel E

In The Press Publications News & Blog

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101)

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101) Read More »

First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors

Leave a Comment / Publication / Joel E

First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors Read More »

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Leave a Comment / Publication / Joel E

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study Read More »

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Leave a Comment / Publication / Joel E

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors Read More »

First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers

Leave a Comment / Publication / Joel E

First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers Read More »

Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol

Leave a Comment / Publication / Joel E

Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol Read More »

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

About START

About

Our Services

Who We Serve

Visit The START Hope Hub

Patients & Family

Referring Physicians

Hospitals & Oncology Practices

Pharma

Resources

Resources

Featured Resources

Baptist Health South Florida and The START Center for Cancer Research Announce Strategic Partnership to Expand Patient Access to Early-Phase Cancer Trials

START Research Expands Clinical Leadership with Appointment of Dr. Neel Belani as Clinical Investigator at START New Jersey

Nehal Lakhani, MD, PhD

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.